Goflikicept: meta-analysis of COVID-19 studies

Meta-analysis1 study · 247 patientsc19early.org

Goflikicept for COVID-19

Serious outcome risk
Goflikicept
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−135%
Mortality (1)−135%
RCTs (1)−135%
Late (1)−135%
00.511.5+
← Goflikicept
reduces risk
Increased
risk →
October 2026

Goflikicept COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Late treatment−135%2.35 · 0.93–5.9214/1236/124135% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.069
All studies−135%2.35 · 0.93–5.9214/1236/124135% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.06900.511.52+
Rotate screen for more detailsIncrease width for more details
← Goflikicept
reduces risk
Goflikicept
increases risk →
October 2026

Goflikicept COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Late treatment−135%2.35 · 0.93–5.9214/1236/124135% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.069
All studies−135%2.35 · 0.93–5.9214/1236/124135% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.06900.511.52+
Rotate screen for more detailsIncrease width for more details
← Goflikicept
reduces risk
Goflikicept
increases risk →
October 2026

Goflikicept COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Late treatment−135%2.35 · 0.93–5.9214/1236/124135% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.069
All studies−135%2.35 · 0.93–5.9214/1236/124135% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.06900.511.52+
Rotate screen for more detailsIncrease width for more details
← Goflikicept
reduces risk
Goflikicept
increases risk →
October 2026

Goflikicept COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Late treatment−135%2.35 · 0.93–5.9214/1236/124135% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.069
All studies−135%2.35 · 0.93–5.9214/1236/124135% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.06900.511.52+
Rotate screen for more detailsIncrease width for more details
← Goflikicept
reduces risk
Goflikicept
increases risk →
October 2026

Goflikicept COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Late treatment−135%2.35 · 0.93–5.9214/1236/124135% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.069
All studies−135%2.35 · 0.93–5.9214/1236/124135% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.06900.511.52+
Rotate screen for more detailsIncrease width for more details
← Goflikicept
reduces risk
Goflikicept
increases risk →